1 Favoriti P,Carbone G,Greco M,et al.Worldwide burden of colorectal cancer:A review [J].Updates Surg,2016,68(1):1-5.
2 DeSantis C,Lin C,Mariotto A,et al.Cancer treatment and survivorship statistics [J].CA Cancer J Clin,2014,64(4):252-271.
3 Goulopoulou S,Mccarthy CG,Webb RC.Toll-like receptors in the vascular system:sensing the dangers within [J].Pharmacol Rev,2016,68(1):142-167.
4 Medvedev AE.Toll-Like receptor polymorphisms,inflammatory and infectious diseases,allergies,and cancer [J].J Interferon Cytokine Res,2013,33(9):467-484.
5 Zhao S,Zhang Y,Zhang Q,et al.Toll-like receptors and prostate cancer [J].Front Immuno,2014,5:352.
6 Bryant CE,Symmons M,Gay NJ.Toll-like receptor signalling through macromolecular protein complexes [J].Mol Immunol,2015,63(2):162-165.
7 Hug H,Mohajeri MH,Fata GL.Toll-Like receptors:regulators of the immune response in the human gut [J].Nutrients,2018,10(2):203.
8 Liston A,Masters SL.Homeostasis-altering molecular processes as mechanisms of inflammasome activation [J].Nat Rev Immunol,2017,17(3):208-214.
9 Bortoluci KR,Medzhitov R.Control of infection by pyroptosis and autophagy:Role of TLR and NLR [J].Cell Mol Life Sci,2010,67(10):1643-1651.
10 Ioannou S,Voulgarelis M.Toll-Like receptors,tissue injury,and tumourigenesis [J].Mediators Inflamm,2010,2010:581837.
11 Lu Y,Li XR,Liu SS,et al.Toll-like receptors and inflammatory bowel disease [J] Front Immuno,2018,9:72.
12 Pradere JP,Dapito DH,Schwabe RF.The yin and yang of Toll-like receptors in cancer [J],Oncogene,33(27):3485-3495.
13 O'Leary DP,Bhatt L,Woolley JF,et al.TLR-4 signalling accelerates colon cancer cell adhesion via NF-κB mediated transcriptional up-regulation of Nox-1 [J].PLoS One,2012,7(10):e44176.
14 Fumi SK,Yao SY,Alast A,et al.Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer [J].JCI Insight,2017,2(18):e93397.
15 Lea SR,Reynolds SL,Kaur M et al.The effects of repeated Toll-like receptors 2 and 4 stimulation in COPD alveolar macrophages [J].Int J Chron Obstruct Pulmon Dis,2018,13:771-780.
16 Li TT,Ogino S,Qian ZR,et al.Toll-like receptor signaling in colorectal cancer:Carcinogenesis to cancer therapy [J].World J Gastroenterol,2014,20(47):17699-17708.
17 Chen CY,Kao CL,Liu CM.The cancer prevention,anti-inflammatory and anti-oxidation of bioactive phytochemicals targeting the TLR4 signaling pathway [J].Int J Mol Sci,2018,19(9):2729.
18 Wang EL,Qian ZR,Nakasono M,et al.High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer [J].Br J Cancer,2010,102(5):908-915.
19 Slattery ML,Herrick JS,Bondurant KL,et al.Toll-like receptor genes and their association with colon and rectal cancer development and prognosis [J].Int J Cancer,2012,130(12):2974-2980.
20 Fang H,Xu X,Huang X,et al.TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells [J].Cell Mol Immunol,2014,11(2):150-159.
21 Kuugbee E,Shang X,Gamallat Y,et al.Structural change in microbiota by a probiotic cocktail enhances the gut barrier and reduces cancer via TLR2 signaling in a rat model of colon cancer [J].Dig Dis Sci,2016,61(10):2908-2920.
22 Lowe E,Crother T,Rabizadeh S,et al.Toll-like receptor 2 signaling protects mice from tumor development in a mouse model of colitis-induced cancer [J].PLoS One,2010,5(9):e13027.
23 Isambert N,Paul C,Ferrand C,et al.Phase I study of OM-174,a lipid A analogue,with assessment of immunological response,in patients withrefractory solid tumors [J].BMC Cancer,2013,13(1):172.
24 Yuk J,Shin D,Song K,et al.Bacillus calmette-guerin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy [J].Autophagy,2010,6(1):46-60.
25 Thaiss CA,Levy M,Itav S,et al.Integration of innate immune signaling [J].Trends Immunol,2016,37(2):84-101.
26 Belani C,Chakraborty B,Khamar B.ArandomizedtrialofTLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer [J].Ann Oncol,2016,82(2):298-304.
27 Davis M,Vasquez-Dunddel D,Fu J,et al.Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses [J].Clin Cancer Res,2011,17(12):3984-3992.
28 Cheng G,Yang S,Zhang G,et al.Lipopolysaccharide-induced α-catenin downregulation enhances the motility of human colorectal cancer cells in an NF-κB signaling-dependent manner [J].Onco Targets Ther,2016,9:7563-7571.
29 Wang BG,Yi DH,Liu YF,et al.TLR3 gene polymorphisms in cancer:a systematic review and meta-analysis [J].Chin J Cancer,2015,34(3):1-13.
30 Wang Q,Zhang X,Xiao T,et al.Prognostic role of Toll-like receptors in cancer:a meta-analysis [J].Ther Clin Risk Manag,2018,14:1323-1330.
31 Maitra R,Augustine T,Dayan Y,et al.Toll like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer [J].Oncotarget,2017,8(21):35138-35153.
32 Forstneriˇc V,Iviˇcak-Kocjan K,Plaper T,et al.The role of the C-terminal D0 domain of flagellin in activation of Toll like receptor 5 [J].PLoS Pathog,2017,13(8):e1006574.
33 Brackett CM,Kojouharov B,Veith J,et al.Toll-like receptor-5 agonist,entolimod,suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8⁺T-cell axis [J].Proc Natl Acad Sci U S A,2016,113(7):874-883.
34 Ito H,Ando T,Arioka Y,et al.Inhibition of indoleamine.2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model [J].Immunology,2015,144(4);621-630.
35 Dumitru C,Antonysamy M,Tomai M,et al.Potentiation of the antitumor effects of imidazoquinoline immune response modifiers by cyclophosphamide [J].Cancer Biol Ther,2010,10(2):155-165.
36 Maria S,Asimina K,Maria S,et al.Evaluation of the detection of Toll-like receptors(TLRs)in cancer development and progression in patients with colorectal cancer [J].PLoS One,2018,13(6):e0197327.
37 Dong T,Yi T,Yang M,et al.Cooperation of α-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model [J].Biochem J,2015,473(1):7-19.
38 Weihrauch MR,Richly H,Hacker UJ,et al.Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours [J].Eur J Cancer,2015,51(2):146-156.
39 Ray A,Tian Z,Das D,et al.A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib [J].Leukemia,2014,28(8):1716-1724.
40 Kunlin W,Huihao Z,Yajuan F,et al,TLR4/MyD88 signaling determines the metastatic potential of breast cancer cells [J].Mol Med Rep,2018,18(3):3411-3420.
41 Xie L,Jiang F,Zhang L,et al.Targeting of MyD88 homodimerization by novel synthetic Inhibitor TJ-M2010-5 in preventing colitis-associated colorectal cancer [J].J Natl Cancer Inst,2016,108(4):364.
42 Paarnio K,Vyrynen S,Klintrup K,et al.Divergent expression of bacterial wall sensing toll-like receptors 2 and 4 in colorectal cancer [J].World J Gastroenterol,2017,23(26):4831-4838.
43 Eiró N,González L,Andicoechea A,et al.Toll-like receptor-4 expression by stromal fibroblasts is associated with poor prognosis in colorectal cancer [J].J Immunother,2015,36(6):342-349.
44 Cammarota R,Bertolini V,Pennesi G,et al.The tumor microenvironment of colorectal cancer:Stromal TLR-4 expression as a potential prognostic marker [J].J Transl Med,2010,8(1):112.